Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash Flows from Operating Activities:
Net loss	$ (27,965,403)	$ (285,672)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization	9,684	9,842
Imputed interest	0	3,321
Share-based compensation	27,938,890	0
Changes in operating assets and liabilities:
Accounts receivable	(15,000)	0
Prepaid Expense	(6,675)	98,640
Deferred Share Issuance Cost	(5,000)	0
Accounts payable and accrued liabilities	4,071	49,992
Accrued Interest	11,224	0
Net Cash Used in Operating Activities	(28,209)	(123,877)
Cash Flows from Investing Activities:
Net funds from acquisition of Xirangsheng (Shenzhen) Health Technology Co., Ltd.	1,458	0
Net Cash Provided by Investing Activities	1,458	0
Cash Flows from Financing Activities:
Proceeds from loans	53,620	0
Repayment of loans	(30,000)	0
Proceed from related party	2,013	0
Proceeds from loan payable - related parties	23,045	163,625
Repayment of loan payable - related party	(24,000)	0
Net Cash Provided by Financing Activities	24,678	163,625
Net Change in Cash and Cash Equivalents	(2,073)	39,748
Cash and Cash Equivalents, beginning of period	16,103	10,815
Cash and Cash Equivalents, end of period	14,030	50,563
Cash consists of:
Cash	14,030	10,815
Funds held in trust	0	0
Total cash	14,030	10,815
Supplemental Disclosure Information:
Cash paid for interest	0	0
Cash paid for taxes	0	0
Non-Cash Disclosure:
Forgiveness of loan payable to related party	0	104,696
Issuance of common stock as commitment shares	249,750	0
Conversion of convertible notes payable	153,520	0
Issuance of common stock for acquisition of Goldfinch Group Holdings Ltd.	15,000	0
Issuance of common stock for acquisition of SolanAI Global Ltd.	12,500,000	0
Issuance of common stock for acquisition of Xirangsheng (Shenzhen) Health Technology Co., Ltd.	$ 1,700,000	$ 0